Decision Diagnostics Corp (DECN)

[1mort]

Mgmt Discussion in filings is OUTSTANDING: "The U.S. FDA cleared the Shasta Genstrip product for sale in the U.S. on November 30, 2012. The worldwide market for at-home blood glucose testing and test kits is an estimated $22.5 billion. Genstrip50 competes directly with one of the largest worldwide platform manufacturer for at-home blood glucose testing, a product currently used daily by over 3 million diabetes afflicted Americans. In addition, since the medical device employed by this legacy platform manufacturers, Genstrip also competes in the overall at-home testing market by offering an economical solution to former users of the legacy platform providers product. In that regard, Genstrip is unique as our major business focus is directed toward diabetics who have attempted a change of glucose monitoring platforms (systems) or those currently using the legacy products but are dealing with escalating prices and lower insurance reimbursements. "